@article{792b0082b19c4bd39ee608627e715a6a,
title = "An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia",
abstract = " This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32\%) patients achieved complete remission with incomplete blood count recovery, 7 (28\%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31\%) and pain (17\%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.",
keywords = "acute leukaemia, bortezomib, childhood leukaemia, pharmacokinetics, proteasome inhibitor",
author = "Kaspers, \{Gertjan J.L.\} and Denise Niewerth and Wilhelm, \{Bram A.J.\} and \{Scholte-van Houtem\}, Peggy and Marta Lopez-Yurda and Johannes Berkhof and Jacqueline Cloos and \{de Haas\}, Valerie and Math{\^o}t, \{Ron A.\} and Andishe Attarbaschi and Andr{\'e} Baruchel and \{de Bont\}, \{Eveline S.\} and Franca Fagioli and Claudia R{\"o}ssig and Thomas Klingebiel and \{De Moerloose\}, Barbara and Brigitte Nelken and Giuseppe Palumbo and Dirk Reinhardt and Rohrlich, \{Pierre Simon\} and Pauline Simon and \{von Stackelberg\}, Arend and Zwaan, \{Christian Michel\}",
note = "Publisher Copyright: {\textcopyright} 2018 John Wiley \& Sons Ltd",
year = "2018",
month = may,
doi = "10.1111/bjh.15233",
language = "English",
volume = "181",
pages = "523--527",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "4",
}